PDS Biotechnology (PDSB) Income towards Parent Company (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Income towards Parent Company came in at -$73201.0 in Q4 2025, up 99.08% YoY from -$36769.7 in Q4 2024, and up 99.19% on a QoQ basis from -$9.0 million in Q3 2025.
PDS Biotechnology (PDSB) Income towards Parent Company (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Income towards Parent Company data on file, last reported at -$73201.0 in Q4 2025.
- Quarterly Income towards Parent Company rose 99.08% year-over-year to -$73201.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$27.0 million (up 28.2% YoY) and the FY2025 annual result came in at -$28.2 million, up 25.09% from the prior year.
- Income towards Parent Company advanced to -$73201.0 in Q4 2025, from -$9.0 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$73201.0 in Q4 2025 to a low of -$19.1 million in Q4 2022.
- A 5-year average of -$8.7 million and a median of -$8.7 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company sank 888.1% — and 2025, when it surged 99.08%.
- Tracing PDSB's Income towards Parent Company over 5 years: stood at -$6.3 million in 2021, then plunged by 202.83% to -$19.1 million in 2022, then surged by 43.06% to -$10.9 million in 2023, then gained by 27.03% to -$8.0 million in 2024, then surged by 99.08% to -$73201.0 in 2025.
- The last three Income towards Parent Company figures came in at -$73201.0 (Q4 2025), -$9.0 million (Q3 2025), and -$9.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.75 Mn |
| Dec 31, 2025 | -73,201.00 |
| Sep 30, 2025 | -9.01 Mn |
| Jun 30, 2025 | -9.43 Mn |
| Mar 31, 2025 | -8.49 Mn |
| Dec 31, 2024 | -7.95 Mn |
| Sep 30, 2024 | -10.73 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -10.60 Mn |
| Dec 31, 2023 | -10.90 Mn |
| Sep 30, 2023 | -10.85 Mn |
| Jun 30, 2023 | -11.53 Mn |
| Mar 31, 2023 | -9.66 Mn |
| Dec 31, 2022 | -19.14 Mn |
| Sep 30, 2022 | -7.42 Mn |
| Jun 30, 2022 | -5.82 Mn |
| Mar 31, 2022 | -14.92 Mn |
| Dec 31, 2021 | -6.32 Mn |
| Sep 30, 2021 | -6.96 Mn |
| Jun 30, 2021 | -588,931.00 |